Der Kaninchen Polyklonal anti-CILP Antikörper (ABIN7227908) detektiert spezifisch CILP in WB und ELISA.
Dieser Antikörper reagiert spezifisch mit Proben aus Human und Maus.
CILP
Reaktivität: Human
WB
Wirt: Ziege
Polyclonal
Biotin
Applikationshinweise
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000,ELISA 1:5000-20000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
PBS, 50 % glycerol, 0.05 % Proclin 300, 0.05 %BSA
Konservierungsmittel
ProClin
Vorsichtsmaßnahmen
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Cartilage intermediate layer protein 1, CILP-1, Cartilage intermediate-layer proteinMajor alterations in the composition of the cartilage extracellular matrix occur in joint disease, such as osteoarthrosis. CILP encodes the cartilage intermediate layer protein (CILP), which increases in early osteoarthrosis cartilage. The encoded protein was thought to encode a protein precursor for two different proteins, an N-terminal CILP and a C-terminal homolog of NTPPHase, however, later studies identified no nucleotide pyrophosphatase phosphodiesterase (NPP) activity. The full-length and the N-terminal domain of this protein was shown to function as an IGF-1 antagonist. An allelic variant of this gene has been associated with lumbar disc disease.